



For Immediate Release

VIRTUAL MEETING REGISTRATION AND VOTING GUIDE

MELBOURNE, Australia, 30 September 2020: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company attaches a Virtual Meeting Voting and Registration guide in respect of the 2020 Annual General Meeting to be held today, 30 September 2020 at 11am (AEST).

The Company wishes to remind Shareholders that the Annual General Meeting is accessible virtually and advises Shareholders to adhere to the State Government COVID-19 restrictions currently in place.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster, Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Authorised for lodgement by the Board of the Company

—END—

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com



About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. In addition to this announcement, Dimerix is currently developing its proprietary product DMX-200 for Diabetic Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) and Acute Respiratory Distress Syndrome (ARDS). DMX-200 was identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving irbesartan, an angiotensin II type I (AT1) receptor blocker and the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by Dimerix' granted patents in various territories until 2032. In 2017, Dimerix completed its first Phase 2a study in patients with a range of chronic kidney diseases. No significant adverse safety events were reported, and all study endpoints were achieved. In a subsequent sub-group analysis, significant clinical efficacy signals were seen in the diabetic group. DMX-200 administered to patients already taking stable irbesartan reduced proteinuria levels by a further 36%. This reduction in proteinuria is highly correlated with improved renal function and delay in kidney failure and dialysis. The compelling results from this study prompted the decision to initiate two different clinical studies in 2018: one for patients with Diabetic Kidney Disease; and the second for patients with another form of kidney disease, Focal Segmental Glomerulosclerosis (FSGS).

FSGS is a serious and rare disease that attacks the kidney's filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and kidney failure and for which there is a recognised medical need for a new or improved treatment. FSGS affects both children and adults.

DMX-200 for FSGS has been granted Orphan Drug Designation by the FDA and EMA. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and an abbreviated regulatory pathway to approval.

DMX-200 is also under investigation as a potential treatment for acute respiratory distress syndrome (ARDS) in patients with COVID-19.

About DMX-700

COPD is a progressive and life-threatening lung disease. The primary cause of COPD is exposure to tobacco smoke (either active smoking or secondary smoke), however it is also caused by exposure to indoor and outdoor air pollution, occupational dusts and fumes and long-term asthma. COPD is the fourth-leading cause of death in the world and although treatments exist to improve the symptoms of COPD, there is currently no way to slow progression of the condition or cure it. Moreover, among the top five causes of death globally, this disease is the only one with increasing mortality rates. The global COPD treatment market was valued at US\$14 billion in 2017 and is projected to increase at a compound annual growth rate of 4.9% to 2026.


Initial studies have been completed, and Dimerix has completed a key step in securing ownership over what it believes is an important new drug discovery by lodging a provisional patent application for DMX-700. Over the next 12 months Dimerix will conduct further proof of concept studies to perform the value-added verification in support of a robust product development pathway and patent position.

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs

Dimerix HQ


425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com

Virtual Meeting Registration and Voting



REGISTRATION


- Go to: <https://investor.automic.com.au/#/home>.
- Log in using your existing username and password or click on “register” and follow the on-screen prompts to create your login credentials.



- Once logged in you will see that the meeting is open for registration. Click on “view”.




- Click on “register” to register your attendance for the meeting.




REGISTRATION

- Select “yes, I would like to vote” and then click “next”.



The screenshot shows the 'Registration' page for 'Sample Corporation LTD - Annual General Meeting'. It is 'Step 1 of 2'. A progress bar at the top shows 'Registration' as the current step and 'Complete' as the next. The main question is 'Will you be registering to vote?'. Below it, there is explanatory text: 'If you have already lodged a Proxy Form and wish to give proxy vote to attend, please select "NO, I will not be voting". If you have lodged a Proxy Form and wish to exercise your vote, please select "YES, I would like to vote".' There are two radio button options: 'YES, I would like to vote' (which is selected) and 'NO, I will not be voting'. A green cursor points to the 'YES' option. At the bottom right, there is a blue 'Next' button with a green cursor pointing to it.

- You will be placed on a holding page until voting opens for the meeting. From here you can access the meeting video/audio by selecting the meeting URL.
- Once the Chair of the Meeting declares voting open, you should select “refresh”.



The screenshot shows the 'Registration' page for 'Sample Corporation LTD - Annual General Meeting'. It is 'Complete - Step 2 of 2'. A progress bar at the top shows 'Registration' as the previous step and 'Complete' as the current step. The main message is 'Registration Complete!' with a green checkmark icon. Below it, there is text: 'The voting is not open yet. Refresh this page or come back here later.' At the bottom, there is a blue box with the text: 'You can join the meeting online using the following link:' followed by a URL: 'https://us02web.zoom.us/j/84986335645?pwd=QTFUL2ZyblYyZjNkd2o0VXh0MGw2Zz09'. A green cursor points to a blue 'Refresh' button located to the right of the 'Registration Complete!' message.

- The next screen will display the resolutions to be put to the meeting.
- The Chair of the meeting will provide instructions on when to mark your vote.
- You record your vote by selecting either “for”, “against” or “abstain” next to the appropriate resolution.
- Once voting has been declared closed you must select “next” to submit your vote.

Voting

Sample Corporation LTD - Annual General Meeting

Registration Poll Review Complete

Poll - Step 2 of 4

You can join the meeting online using the following link:
<https://m02web.zoom.us/j/94066335645?pwd=QTFUeGh5aWwzZDQ2c0Y0d0M0N0eWZkdDQ>

Resolutions
 You must vote on all resolutions, except for those marked as withdrawn:

1 Remuneration Report

2 Re-Election of Mr Robert Smith as Director

0/100

- On the next screen, check your vote is correct and select the box next to “**declaration**” – you cannot confirm your vote unless you select this box.
- Select “**confirm**” to confirm your vote – you CANNOT amend your vote after pressing the “**confirm**” button.

Review - Step 3 of 4

Confirmation
Please choose what confirms:

1. Recommendation Report

2. Re-Election of Mr Robert Smith as Director

Declaration ☒ I agree to be bound by the terms and conditions of the Company's Memorandum and Articles of Association, and to be bound by the decisions of the Directors and the Shareholders of the Company.

Declaration ☐ I agree to be bound by the terms and conditions of the Company's Memorandum and Articles of Association, and to be bound by the decisions of the Directors and the Shareholders of the Company.

VOTING COMPLETE

- Your vote is now lodged and is final.

